EMERGENT BIOSOLUTIONS INC. Proceeds from Stock Options Exercised
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds from Stock Options Exercised of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2024-03-08
- EMERGENT BIOSOLUTIONS INC. proceeds from stock options exercised for the quarter ending 2020-12-31 was $1.00M, a 60.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from stock options exercised for the quarter ending 2020-09-30 was $3.50M, a 218.18% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from stock options exercised for the quarter ending 2020-06-30 was $14.00M, a 278.38% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from stock options exercised for the quarter ending 2020-03-31 was $9.10M, a 911.11% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds from stock options exercised for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. proceeds from stock options exercised for fiscal 2022 was $500.00K, a 95.19% decline from fiscal 2021.
- EMERGENT BIOSOLUTIONS INC. proceeds from stock options exercised for fiscal 2021 was $10.40M, a 62.32% decline from fiscal 2020.
- EMERGENT BIOSOLUTIONS INC. proceeds from stock options exercised for fiscal 2020 was $27.60M, a 236.59% increase from fiscal 2019.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 3 month as first filed | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 6 month as first filed | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 9 month as first filed | Proceeds from Stock Options Exercised 12 month | Proceeds from Stock Options Exercised 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-08 | |||||||
| 2022-12-31 | $500.00K 10-K · filed 2024-03-08 | |||||||
| 2021-12-31 | $10.40M 10-K · filed 2024-03-08 | |||||||
| 2020-12-31 | $1.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $4.50M derived: sum of 2 quarters · filed 2023-12-11 | $18.50M derived: sum of 3 quarters · filed 2023-12-11 | $27.60M 10-K/A · filed 2023-12-11 | ||||
| 2020-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $17.50M derived: sum of 2 quarters · filed 2020-11-06 | $26.60M 10-Q · filed 2020-11-06 | $29.10M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2020-06-30 | $14.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $23.10M 10-Q · filed 2020-07-31 | $25.60M derived: sum of 3 quarters · filed 2020-07-31 | $26.70M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2020-03-31 | $9.10M 10-Q · filed 2020-05-01 | $11.60M derived: sum of 2 quarters · filed 2020-05-01 | $12.70M derived: sum of 3 quarters · filed 2020-11-06 | $16.40M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $3.60M derived: sum of 2 quarters · filed 2020-11-06 | $7.30M derived: sum of 3 quarters · filed 2020-11-06 | $8.20M 10-K · filed 2020-02-25 | ||||
| 2019-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $4.80M derived: sum of 2 quarters · filed 2020-11-06 | $5.70M 10-Q · filed 2020-11-06 | $10.20M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $3.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $4.60M 10-Q · filed 2020-07-31 | $9.10M derived: sum of 3 quarters · filed 2020-07-31 | $12.00M derived: sum of 4 quarters · filed 2020-07-31 | ||||
| 2019-03-31 | $900.00K 10-Q · filed 2020-05-01 | $5.40M derived: sum of 2 quarters · filed 2020-05-01 | $8.30M derived: sum of 3 quarters · filed 2020-05-01 | $12.10M derived: sum of 4 quarters · filed 2020-05-01 | ||||
| 2018-12-31 | $4.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $7.40M derived: sum of 2 quarters · filed 2020-02-25 | $11.20M derived: sum of 3 quarters · filed 2020-02-25 | $15.90M 10-K · filed 2020-02-25 | ||||
| 2018-09-30 | $2.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $6.70M derived: sum of 2 quarters · filed 2019-11-07 | $11.40M 10-Q · filed 2019-11-07 | $11.40M 10-Q · filed 2018-11-02 | $19.90M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-06-30 | $3.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-02 | $8.50M 10-Q · filed 2019-08-02 | $8.46M 10-Q · filed 2018-08-03 | $17.00M derived: sum of 3 quarters · filed 2020-02-25 | $23.20M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-03-31 | $4.70M 10-Q · filed 2019-05-08 | $4.69M 10-Q · filed 2018-05-04 | $13.20M derived: sum of 2 quarters · filed 2020-02-25 | $19.39M derived: sum of 3 quarters · filed 2020-02-25 | $21.04M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $14.70M derived: sum of 2 quarters · filed 2020-02-25 | $16.34M derived: sum of 3 quarters · filed 2020-02-25 | $19.30M 10-K · filed 2020-02-25 | $19.35M 10-K · filed 2018-02-23 | |||
| 2017-09-30 | $6.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-02 | $7.84M derived: sum of 2 quarters · filed 2018-11-02 | $10.80M 10-Q · filed 2018-11-02 | $12.92M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $4.61M 10-Q · filed 2018-08-03 | $6.72M derived: sum of 3 quarters · filed 2019-02-22 | $7.18M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $2.96M 10-Q · filed 2018-05-04 | $5.08M derived: sum of 2 quarters · filed 2019-02-22 | $5.53M derived: sum of 3 quarters · filed 2019-02-22 | $16.46M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2016-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $2.58M derived: sum of 2 quarters · filed 2019-02-22 | $13.51M derived: sum of 3 quarters · filed 2019-02-22 | $17.10M 10-K · filed 2019-02-22 | $17.13M 10-K · filed 2017-02-28 | |||
| 2016-09-30 | $457.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $11.39M derived: sum of 2 quarters · filed 2017-11-03 | $14.98M 10-Q · filed 2017-11-03 | $25.04M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-06-30 | $10.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $14.52M 10-Q · filed 2017-08-04 | $24.58M derived: sum of 3 quarters · filed 2018-02-23 | $27.32M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2016-03-31 | $3.60M 10-Q · filed 2017-05-05 | $13.65M derived: sum of 2 quarters · filed 2018-02-23 | $16.39M derived: sum of 3 quarters · filed 2018-02-23 | $23.21M derived: sum of 4 quarters · filed 2018-02-23 | ||||
| 2015-12-31 | $10.06M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $12.80M derived: sum of 2 quarters · filed 2018-02-23 | $19.62M derived: sum of 3 quarters · filed 2018-02-23 | $25.96M 10-K · filed 2018-02-23 | ||||
| 2015-09-30 | $2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $9.56M derived: sum of 2 quarters · filed 2016-11-09 | $15.90M 10-Q · filed 2016-11-09 | $19.32M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-06-30 | $6.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $13.16M 10-Q · filed 2016-08-05 | $16.58M derived: sum of 3 quarters · filed 2017-02-28 | $17.27M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2015-03-31 | $6.34M 10-Q · filed 2016-05-06 | $9.77M derived: sum of 2 quarters · filed 2017-02-28 | $10.45M derived: sum of 3 quarters · filed 2017-02-28 | $12.29M derived: sum of 4 quarters · filed 2017-02-28 | ||||
| 2014-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $4.11M derived: sum of 2 quarters · filed 2017-02-28 | $5.94M derived: sum of 3 quarters · filed 2017-02-28 | $14.08M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $687.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $2.52M derived: sum of 2 quarters · filed 2015-11-06 | $10.66M 10-Q · filed 2015-11-06 | $15.00M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $9.97M 10-Q · filed 2015-08-06 | $14.31M derived: sum of 3 quarters · filed 2016-02-29 | $15.88M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $8.14M 10-Q · filed 2015-05-08 | $12.48M derived: sum of 2 quarters · filed 2016-02-29 | $14.05M derived: sum of 3 quarters · filed 2016-02-29 | $14.48M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $5.92M derived: sum of 2 quarters · filed 2016-02-29 | $6.34M derived: sum of 3 quarters · filed 2016-02-29 | $6.85M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $2.00M derived: sum of 2 quarters · filed 2014-11-10 | $2.50M 10-Q · filed 2014-11-10 | $2.77M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-06-30 | $429.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | $933.00K 10-Q · filed 2014-08-08 | $1.20M derived: sum of 3 quarters · filed 2015-03-09 | $1.29M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-03-31 | $504.00K 10-Q · filed 2014-05-12 | $770.00K derived: sum of 2 quarters · filed 2015-03-09 | $864.00K derived: sum of 3 quarters · filed 2015-03-09 | $1.02M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2012-12-31 | $266.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $360.00K derived: sum of 2 quarters · filed 2015-03-09 | $519.00K derived: sum of 3 quarters · filed 2015-03-09 | $761.00K 10-K · filed 2015-03-09 | ||||
| 2012-09-30 | $94.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | $253.00K derived: sum of 2 quarters · filed 2013-11-08 | $495.00K 10-Q · filed 2013-11-08 | $1.69M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-06-30 | $159.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $401.00K 10-Q · filed 2013-08-06 | $1.59M derived: sum of 3 quarters · filed 2014-03-10 | $1.73M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-03-31 | $242.00K 10-Q · filed 2013-05-03 | $1.43M derived: sum of 2 quarters · filed 2014-03-10 | $1.57M derived: sum of 3 quarters · filed 2014-03-10 | $6.07M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2011-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $1.33M derived: sum of 2 quarters · filed 2014-03-10 | $5.83M derived: sum of 3 quarters · filed 2014-03-10 | $10.03M 10-K · filed 2014-03-10 | ||||
| 2011-09-30 | $141.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $4.64M derived: sum of 2 quarters · filed 2012-11-01 | $8.84M 10-Q · filed 2012-11-01 | $12.02M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-06-30 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $8.70M 10-Q · filed 2012-08-03 | $11.87M derived: sum of 3 quarters · filed 2013-03-08 | $13.15M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-03-31 | $4.20M 10-Q · filed 2012-05-04 | $7.38M derived: sum of 2 quarters · filed 2013-03-08 | $8.65M derived: sum of 3 quarters · filed 2013-03-08 | |||||
| 2010-12-31 | $3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $4.45M derived: sum of 2 quarters · filed 2013-03-08 | $7.24M 10-K · filed 2013-03-08 | |||||
| 2010-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $4.06M 10-Q · filed 2011-11-04 | ||||||
| 2010-06-30 | $2.78M 10-Q · filed 2011-08-05 | |||||||
| 2009-12-31 | $4.46M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |